Machines combating disease - IoTUK

Alejandro (Sasha) Vicente Grabovetsky, Co-founder of Avalon AI, discusses the ways in which machine learning is improving the rates of failed dementia clinical trials and improving the lives of those living with the disease. The idea for Avalon AI came together when my Co-founder Olivier van den Biggelaar and I realised that we shared the same aim, which was to help defeat ageing. Following that, what immediately came to mind was dementia because it's a disease that has not been successfully tackled yet. Lots of age related diseases like diabetes and cancer receive a lot of funding and are being heavily addressed, while dementia is under-funded partly due to failed clinical trials. Very few dementia clinical trials have succeeded and we noticed that a lot of the past trials were targeting late-stage dementia, where a lot of brain damage had already occurred.